{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059716","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.682186+00:00","generated_at":"2026-06-02T00:43:39.200140+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kintara Therapeutics Q3 FY2024 net loss $2.0M ($0.05/sh), cash $6.35M; merger with TuHURA on track","bullets":["Net loss of $2.0M (diluted EPS -$0.05) vs $3.3M (-$1.94) in prior-year Q3; narrower loss due to lower R&D.","Cash and equivalents $6.35M at March 31, 2024, up from $1.54M at June 30, 2023.","R&D expense fell to $0.59M from $2.01M YoY; G&A rose to $1.49M on merger-related professional fees.","Merger with TuHURA expected to close in Q3 2024; existing stockholders receive contingent value rights tied to REM-001 milestone.","REM-001 CMBC study expanded to include pembrolizumab patients; $2.0M NIH SBIR grant covers most study costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059716","json":"https://secwatch.observer/filing/0000950170-24-059716.json","markdown":"https://secwatch.observer/filing/0000950170-24-059716.md","text":"https://secwatch.observer/filing/0000950170-24-059716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/0000950170-24-059716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/ktra-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:43:39.200140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ee07f9717d994d334938a2b25f3696ba2f118d8","claim":"TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2024 results: net income net loss of approximately $2.0 million, EPS $0.05 per share.","evidence_excerpt":"As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million. For the three months ended March 31, 2024, Kintara reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024059716/0000950170-24-059716-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of approximately $2.0 million"},{"label":"EPS","value":"$0.05 per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}